Proteus Digital Health Inc. and Otsuka Pharmaceutical Co. Ltd. have received FDA approval to market a 'digital pill' technology to treat mental health disorders. Abilify Mycite is a drug-device combination product that consists of Tokyo-based Otsuka's oral aripiprazole tablets, embedded with Redwood City, Calif.-based Proteus' ingestible event marker sensor. Otsuka's Abilify is used to treat depression, bipolar disorder and schizophrenia. Read More
